STING1 and neoplasm: Notably, the addition of STING agonist to olaparib and AZD1775 performed significantly better in terms of overall survival compared with STING agonist monotherapy, with tumour regression in 2/6 and complete tumour clearance of 1/6 of the AT3 tumours (>50 days), whereas no tumour regression or tumour clearance was observed for ADU-S100 monotherapy group (Supplementary Fig. 5a).